Compare · MDWD vs RGC
MDWD vs RGC
Side-by-side comparison of MediWound Ltd. (MDWD) and Regencell Bioscience Holdings Limited (RGC): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MDWD and RGC operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- RGC is the larger of the two at $4.72B, about 29.9x MDWD ($157.6M).
- Both names hit the wire about 1 times in the past 4 weeks.
- MDWD has more recent analyst coverage (8 ratings vs 0 for RGC).
- Company
- MediWound Ltd.
- Regencell Bioscience Holdings Limited
- Price
- -
- -
- Market cap
- $157.6M
- $4.72B
- 1M return
- -
- +63.52%
- 1Y return
- -
- -46.48%
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2014
- 2021
- News (4w)
- 1
- 1
- Recent ratings
- 8
- 0
MediWound Ltd.
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Latest MDWD
- MediWound Awarded Additional $3.3 Million from U.S. Department of War to Advance Room-Temperature-Stable Formulation of NexoBrid®
- Independent DSMB Recommends MediWound’s EscharEx® Phase III VALUE Study Continue Without Modification
- Director Rubinstein Samuel sold $6,678 worth of Ordinary Shares (525 units at $12.72) and bought $6,626 worth of Ordinary Shares (525 units at $12.62) (SEC Form 4)
- MediWound to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- COO & Chief Commercial Officer Hess Shmuel sold $75,394 worth of Ordinary Shares (5,823 units at $12.95), closing all direct ownership in the company (SEC Form 4)
- SEC Form 6-K filed by MediWound Ltd.
- MediWound Reports Second Quarter 2026 Financial Results and Provides Corporate Update
- MediWound to Report Second Quarter 2026 Financial Results
- Director Shamir Nachum bought $83,996 worth of Ordinary Shares (6,000 units at $14.00), increasing direct ownership by 12% to 55,815 units (SEC Form 4)
- Director Fox David Morton bought $49,901 worth of Ordinary Shares (3,537 units at $14.11), increasing direct ownership by 19% to 22,283 units (SEC Form 4)
Latest RGC
- SEC Form 20-F filed by Regencell Bioscience Holdings Limited
- SEC Form 4 filed by Director Lo William Wing Yan Dr
- SEC Form 4 filed by Director Hui Evana Yee Wah
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 424B5 filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited
- SEC Form 6-K filed by Regencell Bioscience Holdings Limited